Intech Investment Management LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Intech Investment Management LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 32,395 shares of the biopharmaceutical company's stock, valued at approximately $644,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company's stock valued at $127,212,000 after purchasing an additional 860,244 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after purchasing an additional 263,099 shares during the last quarter. Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the period. Renaissance Technologies LLC raised its stake in Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock valued at $33,702,000 after buying an additional 287,300 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company's stock valued at $19,439,000 after buying an additional 22,860 shares during the period. Institutional investors own 79.22% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on CPRX shares. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Truist Financial increased their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $31.14.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company's stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded down $0.27 during mid-day trading on Friday, reaching $22.07. The company's stock had a trading volume of 554,323 shares, compared to its average volume of 1,132,546. The firm has a market capitalization of $2.63 billion, a PE ratio of 18.70, a P/E/G ratio of 3.40 and a beta of 0.75. The stock has a fifty day moving average of $21.26 and a two-hundred day moving average of $18.77. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.00 and a 52 week high of $24.27.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.